Acquisition in Bangladesh is minor, won't impact FY18 numbers: Dr Lal Pathlab

Dr Lal Pathlab's Q1 earnings were boosted as margins bounced back due to seasonality and strong traction was seen in the core Delhi market.

In an interview to CNBC-TV18, Doctor Om Manchanda, CEO of Dr Lal Pathlabs spoke about the results and his outlook for the company.

Speaking about recent acquisition, he said the acquisition in Bangladesh is a minor one and it will not impact FY18 numbers.

Have seen improvement in volume performance after demonetisation, said Manchanda.